Research programme: Nociceptin/orphanin FQ peptide receptor agonist central therapeutics - Grunenthal
Alternative Names: NOP central - GrunenthalLatest Information Update: 27 Jun 2022
At a glance
- Originator Grunenthal
- Class Analgesics
- Mechanism of Action Nociceptin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 27 Jun 2022 Nociceptin/orphanin FQ peptide receptor agonist central therapeutics - Grunenthal is available for licensing as of 27 Jun 2022. https://www.grunenthal.com/en/research-and-development/pain-research-and-development
- 27 Jun 2022 Preclinical trials in Pain in Germany (unspecified route) as of June 2022 (Grunenthal pipeline, June 2022)